A paediatric case of successful non-myeloablative bone marrow transplantation after azacitidine therapy for non-Down syndrome acute megakaryoblastic leukaemia with monosomy 7

2016 ◽  
Vol 20 (6) ◽  
pp. 868-870 ◽  
Author(s):  
Yuhki Koga ◽  
Utako Oba ◽  
Wakako Kato ◽  
Hiroaki Ono ◽  
Kentaro Nakashima ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Down Syndrome ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Monosomy 7 ◽  
Paediatric Case ◽  
Megakaryoblastic Leukaemia ◽  
Acute Megakaryoblastic Leukaemia

Partially matched bone marrow transplantation in patients with myelodysplastic syndromes.

1988 ◽  
Vol 6 (12) ◽  
pp. 1851-1855 ◽  
Author(s):  
N J Bunin ◽  
J T Casper ◽  
C Chitambar ◽  
J Hunter ◽  
R Truitt ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Rabbit Serum ◽  
Normal Rabbit Serum ◽  
Trisomy 8 ◽  
Monosomy 7 ◽  
Patients Âgés ◽  
Curative Therapy ◽  
Unrelated Donors

Six patients with a myelodysplastic syndrome (MDS) were treated with bone marrow transplantation (BMT) using partially-matched related (3) or unrelated (3) donors. Patients' ages ranged from 7 to 31 years (median, 10 years). Bone marrow karyotype abnormalities were present in five patients included four with monosomy 7 and one with trisomy 8. One patient was in complete remission before transplant; the remaining five had excess of blasts or were undergoing leukemic transformation. Donor, and recipient were mismatched at the DR locus (2), A locus (2), B locus (1), or A and B loci (1). Conditioning included busulfan, cytarabine, cyclophosphamide, methylprednisolone, and total body irradiation. Cyclosporine was started on day -1. Marrows were T-cell depleted using a monoclonal antibody (MoAb) (CD3) and normal rabbit serum. Four patients engrafted routinely. One patient died of aspergillosis before engraftment (day 12) and one patient failed to engraft on first attempt, but engrafted following additional preparation. Median time to neutrophils greater than 500/microL and platelets greater than 25,000/microL were 16 and 19 days, respectively. Acute graft-v-host disease (GVHD) was less than or equal to grade II in all patients. One patient died with recurrent disease (day 257). One patient died at day 515 of pancreatitis and respiratory failure. Three patients are alive and disease-free at 240, 395, and 560 days post-BMT including two patients with unrelated donors. Partially matched T-depleted bone marrow from related or unrelated donors may be effective, and possibly curative therapy for patients with MDS who lack a histocompatibility locus antigen (HLA)-identical sibling donor.

scholarly journals Bone marrow transplantation for children with myelodysplastic syndromes

Blood ◽  
1989 ◽  
Vol 73 (2) ◽  
pp. 619-622 ◽  
Author(s):  
EC Guinan ◽  
NJ Tarbell ◽  
R Tantravahi ◽  
HJ Weinstein
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Myelodysplastic Syndromes ◽  
Marrow Transplantation ◽  
De Novo ◽  
Chromosomal Abnormalities ◽  
Allogeneic Bone Marrow Transplantation ◽  
Allogeneic Bone ◽  
Monosomy 7 ◽  
Agent Based

Abstract Therapeutic options for children with de novo or secondary myelodysplastic syndromes (MDSs) are limited. We report the outcome of eight pediatric patients (median age 12 years, range 3 to 19 years) with myelodysplasia who underwent allogeneic bone marrow transplantation between 1984 and 1987. Two of the eight children had developed secondary myelodysplasia after alkylating agent-based combination chemotherapy. Five patients had clonal chromosomal abnormalities, including four patients with monosomy 7. Seven of eight patients engrafted. Two of these seven subsequently died of complications of acute or chronic graft-v-host disease (GVHD), and a third patient died at 21 months of pulmonary fibrosis. None of the patients have had recurrence of disease. The four surviving patients remain in complete remission at a median follow-up of 19 months (range 10 to 44 months).

Effective response to azacitidine in a child with a second relapse of myeloid leukemia associated with Down syndrome after bone marrow transplantation

2018 ◽  
Vol 65 (12) ◽  
pp. e27414 ◽  
Author(s):  
Suguru Uemura ◽  
Takeshi Mori ◽  
China Nagano ◽  
Satoru Takafuji ◽  
Noriyuki Nishimura ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Down Syndrome ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Myeloid Leukemia ◽  
Effective Response

scholarly journals Monosomy 7 in donor cell-derived leukemia after bone marrow transplantation for severe aplastic anemia: report of a new case and review of the literature

2012 ◽  
Vol 35 (4) ◽  
pp. 734-736 ◽  
Author(s):  
Luize Otero ◽  
Daiane Correa de Souza ◽  
Rita de Cássia Tavares ◽  
Bernadete Evangelho Gomes ◽  
Telma França Padilha ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Aplastic Anemia ◽  
Marrow Transplantation ◽  
Donor Cell ◽  
Severe Aplastic Anemia ◽  
Review Of The Literature ◽  
Monosomy 7

Prolonged Bone Marrow Failure With Monosomy 7 After Engraftment Failure Following Bone Marrow Transplantation

2001 ◽  
Vol 73 (2) ◽  
pp. 258-261
Author(s):  
Ryoji Kobayashi ◽  
Hideki Arioka ◽  
Makoto Yoshida ◽  
Yuko Cho ◽  
Akihiro Iguchi ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Bone Marrow Failure ◽  
Monosomy 7 ◽  
Engraftment Failure

Bone Marrow Transplantation for Children With Acute Leukemia and Down Syndrome

PEDIATRICS ◽  
1986 ◽  
Vol 78 (4) ◽  
pp. 688-691
Author(s):  
Charles M. Rubin ◽  
Maura O'Leary ◽  
Penelope A. Koch ◽  
Mark E. Nesbit
Keyword(s):  
Bone Marrow ◽  
Down Syndrome ◽  
Bone Marrow Transplantation ◽  
Acute Leukemia ◽  
Marrow Transplantation ◽  
Intensive Therapy ◽  
Pulmonary Complications ◽  
High Dose ◽  
Membrane Toxicity ◽  
Total Body

Four children with acute leukemia and Down syndrome received high-dose cyclophosphamide therapy and total body irradiation in preparation for bone marrow transplantation. Skin and mucous membrane toxicity was pronounced. Furthermore, three children died during the immediate posttransplantation period of infectious and hemorrhagic pulmonary complications. One patient had hematologic recovery and is surviving disease-free 1 year following transplantation. These preliminary observations are in agreement with previous data suggesting that children with Down syndrome are at higher risk for toxicity, pneumonitis, and, possibly, death following administration of intensive therapy for leukemia in comparison with children without Down syndrome. Improvements in the management of these children in the future will depend upon a better understanding of the biologic and pathophysiologic aspects of Down syndrome and additional clinical experience.

Sign in / Sign up

Export Citation Format

Share Document